Skip to main content
. 2013 Mar 12;108(6):1238–1244. doi: 10.1038/bjc.2013.83

Table 1. Clinicopathological characteristics of patients.

  Mayo Clinic mFOLFOX6/XELOX  
Characteristic (n=95; n/%) (n=160; n/%) P-value
Gender
 
 
0.34
Male 50/52.6 94/58.8  
Female
45/47.4
66/41.2
 
Age (years)
 
 
0.18
Median 56.1 53.9  
Range
27–78
26–83
 
Pathology
 
 
0.31
G2 72/75.8 116/72.5  
G1 5/5.3 20/12.5 0.31
G3
18/19.1
24/15
 
Stage
 
 
0.12
IIIA 64/67.3 97/60.6  
IIIB 24/25.3 53/33.1  
IIIC
7/7.4
10/6.3
 
CEA
 
 
0.76
<5 ng ml−1 63/66.3 108/67.5  
>5 ng ml−1
32/33.7
52/32.5
 
ERCC1
 
 
0.66
Positive 52/54.7 88/55  
Negative
43/45.3
72/45
0.66
MMR
 
 
0.53
pMMR 81/85.2 133/83.1  
dMMR
14/14.8
27/16.9
 
Metastasis
 
 
0.08
Yes 45/47.4 64/40  
No
50/52.6
96/60
 
Live
 
 
0.02
Yes 50/52.6 106/66.5  
No 45/47.4 54/33.8  

Abbreviations: CEA=carcinoembryonic antigen; dMMR=deficient MMR; ERCC1=excision repair cross-complementation group 1; MMR=mismatch repair; pMMR=proficient MMR.P-value of the chi-square test comparing characteristics distribution between the Mayo clinic group and mFOLFOX6/XELOX group. Metastasis means the postoperative metastasis.